IL135324A0 - Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders - Google Patents

Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders

Info

Publication number
IL135324A0
IL135324A0 IL13532498A IL13532498A IL135324A0 IL 135324 A0 IL135324 A0 IL 135324A0 IL 13532498 A IL13532498 A IL 13532498A IL 13532498 A IL13532498 A IL 13532498A IL 135324 A0 IL135324 A0 IL 135324A0
Authority
IL
Israel
Prior art keywords
apoa
agonists
native
gene therapy
apolipoprotein
Prior art date
Application number
IL13532498A
Other languages
English (en)
Original Assignee
Dasseux Jean Louis
Sekul Renate
Buttner Klaus
Cornut Isabelle
Metz Gunther
Dufourcq Jean
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dasseux Jean Louis, Sekul Renate, Buttner Klaus, Cornut Isabelle, Metz Gunther, Dufourcq Jean filed Critical Dasseux Jean Louis
Publication of IL135324A0 publication Critical patent/IL135324A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL13532498A 1997-09-29 1998-09-28 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders IL135324A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/940,136 US6518412B1 (en) 1997-09-29 1997-09-29 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
PCT/US1998/020329 WO1999016409A2 (fr) 1997-09-29 1998-09-28 Methodes de therapie genique servant a produire des agonistes d'apolipoproteine a-i et leur utilisation pour traiter des troubles de la dyslipidemie

Publications (1)

Publication Number Publication Date
IL135324A0 true IL135324A0 (en) 2001-05-20

Family

ID=25474297

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13532498A IL135324A0 (en) 1997-09-29 1998-09-28 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders

Country Status (17)

Country Link
US (4) US6518412B1 (fr)
EP (1) EP1039934B1 (fr)
JP (1) JP2003525565A (fr)
KR (1) KR100650975B1 (fr)
CN (1) CN100345588C (fr)
AT (1) ATE323510T1 (fr)
AU (1) AU758307B2 (fr)
CA (1) CA2304814A1 (fr)
DE (1) DE69834267T2 (fr)
ES (1) ES2263221T3 (fr)
HU (1) HU225821B1 (fr)
IL (1) IL135324A0 (fr)
NO (1) NO20001601L (fr)
NZ (1) NZ503720A (fr)
PL (1) PL193662B1 (fr)
RU (1) RU2222545C2 (fr)
WO (1) WO1999016409A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
JP4794707B2 (ja) * 1998-11-17 2011-10-19 ソニー株式会社 端末装置、課金システム、データ処理方法
CA2402772A1 (fr) * 2000-03-13 2001-09-20 Amgen Inc. Regulation apo-a-i de la signalisations des lymphocytes t
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
EP1699527A1 (fr) 2004-01-02 2006-09-13 Advanced Cardiovascular Systems, Inc. Dispositifs medicaux revetus de lipoproteine a haute densite
WO2006034056A2 (fr) * 2004-09-16 2006-03-30 The Regents Of The University Of California Peptides de type g et autres agents permettant d'ameliorer l'atherosclerose et d'autres pathologies
ATE469174T1 (de) 2004-10-15 2010-06-15 Us Gov Health & Human Serv Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
BRPI0517148A (pt) 2004-12-06 2008-09-30 Univ California método de aperfeiçoamento da estrutura e/ou função arterìola; agente ativo e kit para tratamento
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2007137400A1 (fr) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Méthode et composé pour le traitement des sténoses valvulaires
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
WO2007149355A2 (fr) * 2006-06-16 2007-12-27 Lipid Sciences, Inc. Nouveaux peptides qui favorisent un écoulement de lipides
AU2007285775B2 (en) * 2006-08-17 2011-03-03 Sanofi Pasteur Ltd. Immunogenic PcpA polypeptides and uses thereof
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009032693A2 (fr) * 2007-08-28 2009-03-12 Uab Research Foundation Polypeptides de synthèse imitant l'apolipoprotéine e et leurs procédés d'utilisation
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
WO2009129263A1 (fr) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides favorisant l’efflux de lipides via abca1 et activant une lipoprotéine lipase
SI2396017T1 (sl) * 2009-02-16 2015-12-31 Cerenis Therapeutics Holding Sa Mimika apolipoproteina A-1
US8176412B2 (en) * 2009-08-25 2012-05-08 International Business Machines Corporation Generating formatted documents
BR112013004395A2 (pt) * 2010-08-30 2019-09-24 Hoffmann La Roche tetranectina-apolipoproteína a-i, partículas de lipídio que a contém a sua utilização
RU2017126088A (ru) 2011-02-07 2019-01-31 Серени Терапеутикс Холдинг С.А. Липопротеиновые комплексы и их получение и применения
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
MX2014001920A (es) 2011-08-25 2014-04-14 Hoffmann La Roche Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma.
CN104250288B (zh) * 2013-06-28 2018-02-27 清华大学 两亲性α螺旋自组装肽及其应用
EP3137899A2 (fr) 2014-05-02 2017-03-08 Cerenis Therapeutics Holding SA Marqueurs de thérapie hdl
EP3189069B1 (fr) 2014-07-31 2024-10-23 UAB Research Foundation Peptides e-mimétiques d'apo ayant une puissance supérieure afin de dégager le taux de cholestérol plasmatique
CA3028721A1 (fr) * 2016-06-20 2017-12-28 The Regents Of The University Of Michigan Compositions et methodes pour administrer des agents biomacromoleculaires

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (fr) 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (fr) 1979-06-22 1984-08-28 Jurg Schrank Produits pharmaceutiques
DE3241102A1 (de) 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4857319A (en) 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
CA2137814A1 (fr) 1992-06-12 1993-12-23 Maryvonne Rosseneu Nouveaux peptides et nouvelles proteines, leur processus de preparation et leur utilisation en tant qu'accepteurs de cholesterol
US5674855A (en) 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5643757A (en) * 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
AU695618B2 (en) * 1994-04-11 1998-08-20 Baylor College Of Medicine Compositions and methods for gene therapy to treat disease
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Also Published As

Publication number Publication date
ES2263221T3 (es) 2006-12-01
EP1039934B1 (fr) 2006-04-19
PL358529A1 (en) 2004-08-09
KR20010030806A (ko) 2001-04-16
US6518412B1 (en) 2003-02-11
WO1999016409A2 (fr) 1999-04-08
CN100345588C (zh) 2007-10-31
PL193662B1 (pl) 2007-03-30
US7250407B2 (en) 2007-07-31
RU2222545C2 (ru) 2004-01-27
AU9671498A (en) 1999-04-23
US20050148513A1 (en) 2005-07-07
CN1303298A (zh) 2001-07-11
NO20001601L (no) 2000-05-26
DE69834267D1 (de) 2006-05-24
HUP0003924A2 (hu) 2001-01-29
US20030208059A1 (en) 2003-11-06
HU225821B1 (en) 2007-10-29
ATE323510T1 (de) 2006-05-15
EP1039934A1 (fr) 2000-10-04
AU758307B2 (en) 2003-03-20
CA2304814A1 (fr) 1999-04-08
JP2003525565A (ja) 2003-09-02
DE69834267T2 (de) 2007-01-04
EP1039934A4 (fr) 2002-11-27
KR100650975B1 (ko) 2006-11-29
NO20001601D0 (no) 2000-03-28
HUP0003924A3 (en) 2005-12-28
US20080050351A1 (en) 2008-02-28
US6844327B2 (en) 2005-01-18
NZ503720A (en) 2002-10-25

Similar Documents

Publication Publication Date Title
IL135324A0 (en) Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders
ES2525677T3 (es) Celulasas, genes que las codifican y usos de las mismas
DE69838676D1 (de) Neuartige phytase
WO2003104270A3 (fr) Genes de la duduline 2, produits d'expression, modele animal non humain : utilisations dans les maladies hematologiques humaines
GB0202556D0 (en) Novel Protein
DE59209981D1 (de) Rekombinantes core-streptavidin
IL135687A0 (en) A novel human checkpoint kinase, hcds1, compositions and methods
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
PL313445A1 (en) Grb3-3 gene, variants thereof and their use
EP0815233A4 (fr) Nouvelles cytokines aviaires et sequences genetiques codant celles-ci
WO1998011234A3 (fr) Proteines kinases humaines
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
FR2792651A1 (fr) Sequence genomique et polypeptides de pyrococcus abyssi, leurs fragments et leurs utilisations
FR2773079B1 (fr) Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
ATE387494T1 (de) Hitzelabile desoxyribonuklease i-varianten